Compare McDonald's Corp (MCD) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McDonald's Corp vs 10X Genomics Inc — how do they compare? McDonald's Corp trades at $264.98 (market cap $190.16B), while 10X Genomics Inc trades at $46.15 (market cap $5.48B). The key difference: McDonald's Corp is far larger — about 34.7× 10X Genomics Inc's market cap, and McDonald's Corp pays a 2.78% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.
| MCD | TXG | |
|---|---|---|
Market Cap | $190.16B | $5.48B |
Volume | 2,230,036 | — |
Sector | Consumer Cyclical | Health |
52-Week High | $341.06 | $45.80 |
52-Week Low | $264.54 | $11.34 |
Enterprise Value | $243.87B | $5.02B |
Dividend Yield | 2.78% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McDonald's (MCD) trades at $267.71, down 2.1% on the day, with a bearish technical signal driven by moving averages. The company reported steady revenue growth to $26.89 billion in 2025 and a net income margin of 31.62%, though Q2 2026 earnings are pending. Recent news highlights a new 'McDonald's NEXT' strategy focusing on automation and menu improvements to boost competitiveness.
The stock presents a buying opportunity with a consensus price target of $329, implying 23% upside, supported by strong analyst sentiment (58% buy ratings). Risks include inflationary pressures on franchisee margins and high long-term debt of $38.42 billion. Earnings execution and strategy rollout will be key for near-term performance.
TXG trades at $43.18, down 1.28% today, with a bullish technical signal and positive earnings momentum. The stock shows improving fundamentals with revenue growth to $642.82M in 2025 and narrowing losses, while maintaining a strong gross margin of 69.6%. Recent acquisitions and partnerships with Cleveland Clinic demonstrate strategic expansion in genomic diagnostics.
The outlook remains cautiously optimistic with analyst consensus at Buy (45%) and price target of $39.14. Key risks include continued negative profitability metrics and high valuation multiples, while catalysts include upcoming Q2 2026 earnings and platform adoption growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About McDonald's Corp
McDonald's Corporation franchises and operates fast-food restaurants in the global restaurant industry. The Company's restaurants serves a variety of value-priced menu products in countries around the world.
Read more on MCD →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
